News | Oncology Analytics’ Distinguished Academic Advisory Board Grows

Oncology Analytics’ Distinguished Academic Advisory Board Grows

New Members Bring Radiation Oncology and Pathology Expertise

Oncology Analytics, Inc., today announced that it has added three new members to its Distinguished Academic Advisory Board. The three new board members include noted pathologist, Jonathan Epstein, MD, and key opinion leaders in radiation therapy, David Raben, MD, and Jay Harris, MD. “We are pleased that Drs. Epstein, Raben, and Harris have chosen to contribute to OA as Academic Advisory Board members,” says Marc Fishman, MD and CEO of Oncology Analytics. “OA’s unsurpassed level of clinical expertise is essential for complicated and difficult cancer cases.”

Dr. Jonathan Epstein, an international thought leader on active surveillance for prostate cancer, is currently a Professor in Pathology, Urology, and Oncology at Johns Hopkins Hospital. He has authored more than 800 articles, 50 book chapters, and 14 books, including the widely-cited Epstein criteria for active surveillance of prostate cancer. Along with serving on the National Comprehensive Cancer Network (NCCN) for early detection of prostate cancer, Dr. Epstein was a recipient of the International Society of Urologic Pathology Grawitz Medal.

Dr. David Raben is nationally recognized on his work in targeted therapies and radiation, primarily in gastrointestinal, head/neck cancer, and lung cancer. He has extensive experience spanning over 14 years with low and high dose rate brachytherapy, and currently serves on the ASCO (American Society of Clinical Oncology) and ASTRO (American Society for Therapeutic Radiation Oncology) program planning committees. Dr. Raben is a professor of Radiation Oncology at the University of Colorado.

Dr. Jay Harris is a highly-respected, international expert on breast cancer. He trained in radiation oncology at the Harvard Joint Center for Radiation Therapy, joined the Dana-Farber Cancer Institute (DFCI) staff in 1977, and later chaired the department of Radiation Oncology at DFCI from 1997 to 2015. He has served on the ASCO Board of Directors, as President and Chairman of the Board for ASTRO, and as a Trustee for the American Board of Radiology. Dr. Harris is a recipient of the 2007 Gold Medal and the 2008 ACO Gianni Bonadonna Breast Cancer Research Award for his work in breast-conserving therapy, and his extensive research on breast malignancies.

Plantation, Flordia, October 19, 2016

About Oncology Analytics, Inc.

Founded in Plantation, Florida, in 2009, Oncology Analytics, Inc. is a comprehensive oncology benefits management company serving health plans, providers and patients in the U.S. market and Puerto Rico. Oncology Analytics has continued its mission of using evidence-based medicine to drive better treatment options for cancer care at reduced costs. Using a patient-focused approach, Oncology Analytics’ clinical team of board-certified hematologists/oncologists, oncology RNs, and board-certified oncology pharmacists personally review individual cases that require additional assessment for individualized care.

Evidence Based. Results Driven. Patient Focused.


Oncology Analytics, Inc.
Marisela Medrano
Director of Marketing & Sales
(888) 916-2616